PMID- 28616861
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231112
IS  - 2193-8261 (Print)
IS  - 2193-6544 (Electronic)
IS  - 2193-6544 (Linking)
VI  - 6
IP  - 2
DP  - 2017 Dec
TI  - Medical Therapy and Recurrent Ischemic Events in High Risk Patients Surviving 
      their Myocardial Infarction for at Least 12 Months: Comparison of Patients with 
      ST Elevation Versus Non-ST Elevation Myocardial Infarction.
PG  - 273-280
LID - 10.1007/s40119-017-0093-7 [doi]
AB  - INTRODUCTION: Data about treatments and recurrent ischemic events in patients 
      surviving their most recent myocardial infarction event-free for at least 
      12 months are scarce. METHODS: In a retrospective data analysis, charts of 
      patients who had a myocardial infarction 1-3 years ago with an event-free period 
      of at least 12 months after the index event and at least one high risk factor 
      were centrally collected and analyzed. Here we compare patients with ST elevation 
      myocardial infarction (STEMI) versus non-ST elevation myocardial infarction 
      (NSTEMI). RESULTS: A total of 666 patients, 342 with STEMI and 324 with NSTEMI, 
      were included. Revascularization procedures for the index event were performed in 
      89% of patients with STEMI and 72% of patients with NSTEMI. About 62% of patients 
      were still on dual antiplatelet therapy after 12 months, predominantly with 
      aspirin and clopidogrel. This rate declined to 30% after 18 months. Patients with 
      STEMI had a higher mortality (19% versus 13%, p = 0.04) and major adverse 
      cardiovascular and cerebrovascular event rate (MACCE; 33% versus 23%, p = 0.03) 
      during follow-up up to 36 months, while there were no significant differences 
      with respect to recurrent myocardial infarction or stroke. The number of high 
      risk factors was closely linked to the rate of MACCE at follow up. CONCLUSIONS: 
      Patients surviving their myocardial infarction without any further event during 
      the first 12 months have a high rate of recurrent ischemic events in both STEMI 
      and NSTEMI cases during subsequent follow-up. Therefore, secondary prevention 
      therapies should be continued even one year after myocardial infarction, which 
      might improve outcomes.
FAU - Zeymer, Uwe
AU  - Zeymer U
AD  - Klinikum Ludwigshafen and Institut fur Herzinfarktforschung, Ludwigshafen, 
      Germany. uwe.zeymer@t-online.de.
FAU - Riedel, Katrin
AU  - Riedel K
AD  - Astra Zeneca Germany GmbH, Wedel, Germany.
FAU - Hahn, Michael
AU  - Hahn M
AD  - Astra Zeneca Germany GmbH, Wedel, Germany.
LA  - eng
PT  - Journal Article
DEP - 20170614
PL  - England
TA  - Cardiol Ther
JT  - Cardiology and therapy
JID - 101634495
PMC - PMC5688970
OTO - NOTNLM
OT  - Acute myocardial infarction
OT  - Prognosis
OT  - Secondary prevention
EDAT- 2017/06/16 06:00
MHDA- 2017/06/16 06:01
PMCR- 2017/06/14
CRDT- 2017/06/16 06:00
PHST- 2017/03/06 00:00 [received]
PHST- 2017/06/16 06:00 [pubmed]
PHST- 2017/06/16 06:01 [medline]
PHST- 2017/06/16 06:00 [entrez]
PHST- 2017/06/14 00:00 [pmc-release]
AID - 10.1007/s40119-017-0093-7 [pii]
AID - 93 [pii]
AID - 10.1007/s40119-017-0093-7 [doi]
PST - ppublish
SO  - Cardiol Ther. 2017 Dec;6(2):273-280. doi: 10.1007/s40119-017-0093-7. Epub 2017 
      Jun 14.